Peng Lu Sells 7,001 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Peng Lu sold 7,001 shares of Pharvaris stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $30.05, for a total transaction of $210,380.05. Following the sale, the insider owned 66,083 shares of the company’s stock, valued at $1,985,794.15. The trade was a 9.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Peng Lu also recently made the following trade(s):

• On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total transaction of $3,003.00.

Pharvaris Stock Up 5.0%

PHVS traded up $1.37 on Friday, reaching $28.66. 94,448 shares of the company traded hands, compared to its average volume of 171,838. Pharvaris N.V. has a one year low of $14.59 and a one year high of $30.24. The firm has a fifty day simple moving average of $27.39 and a two-hundred day simple moving average of $25.80. The company has a market cap of $1.87 billion, a P/E ratio of -8.53 and a beta of -2.58.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.15). On average, equities analysts forecast that Pharvaris N.V. will post -3.19 earnings per share for the current year.

Wall Street Analyst Weigh In

PHVS has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday. Wolfe Research started coverage on shares of Pharvaris in a research report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective on the stock. Wall Street Zen downgraded shares of Pharvaris from a “sell” rating to a “strong sell” rating in a research report on Monday, April 13th. Finally, Royal Bank Of Canada cut their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pharvaris has a consensus rating of “Moderate Buy” and an average target price of $42.73.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. California State Teachers Retirement System grew its position in shares of Pharvaris by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock worth $666,000 after buying an additional 520 shares during the last quarter. JPMorgan Chase & Co. grew its position in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Pharvaris during the 4th quarter worth approximately $35,000. Public Employees Retirement System of Ohio grew its position in Pharvaris by 20.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Legal & General Group Plc grew its position in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares during the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.